Celsense

Celsense, Inc. was a privately held biotechnology company based in Pittsburgh, Pennsylvania, United States. Founded in 2005, the company was established to commercialize imaging platforms developed at Carnegie Mellon University. Its work focused on imaging agents intended to make cells and cellular activity visible through non-invasive methods, supporting research and potential clinical monitoring applications. The company operated at the intersection of biotechnology, medical imaging, and cell-based medicine. Rather than presenting itself primarily as a conventional pharmaceutical manufacturer, Celsense developed enabling technologies intended to help researchers and clinicians track biological processes in living systems. Such technologies have potential relevance to cell therapies, cancer research, regenerative medicine, and other areas in which the location, persistence, or activity of administered or naturally occurring cells is important. One publicly documented clinical-development milestone occurred in 2011, when Celsense received authorization from the U.S. Food and Drug Administration to begin Phase I clinical trials for a colorectal cancer treatment involving therapeutic dendritic cells. This authorization marked a step toward evaluating a cell-based therapeutic approach with the support of Celsense's imaging capabilities. The available reference material does not establish the eventual clinical outcome, commercial launch of a therapy, or regulatory approval beyond the authorization to begin early-stage trials. Charles O'Hanlon served as the company's president and chief executive officer throughout its existence. Celsense remained privately held and no public stock listing or ticker is identified in the available material. The company ceased operations on December 31, 2021, ending its activity as an operating biotechnology business. Because the available public information is limited, details about its complete product portfolio, financing, partnerships, revenue, ownership structure, and the disposition of its technologies after closure remain unconfirmed.

Celsense was founded in 2005 in Pittsburgh, Pennsylvania, to commercialize imaging platforms developed at Carnegie Mellon University. The company was formed around the proposition that biological and medical research could benefit from methods capable of showing where cells are located and how they behave inside living systems without requiring invasive procedures or destructive sampling. Its area of activity was cellular imaging. Celsense developed imaging agents intended to detect and monitor cells and cellular activity, creating tools that could support investigations of cell behavior and the evaluation of cell-based medical interventions. The available reference material describes the company as a biotechnology developer rather than providing a full catalog of branded products, commercial sales, or approved therapies. Consequently, the precise composition of its product lines and the extent of their market adoption cannot be established from the available sources. Celsense's technology also intersected with therapeutic development. In 2011, the company received authorization from the U.S. Food and Drug Administration to begin Phase I clinical trials for a colorectal cancer treatment using therapeutic dendritic cells. This was an early clinical-stage development milestone. Phase I studies generally focus primarily on initial safety and feasibility questions, but the available information does not document the trial's results, later phases, or whether the treatment reached market approval. Charles O'Hanlon was the company's president and chief executive officer for the lifetime of the company. No other executives, founders, parent organization, public listing, or ownership details are identified in the supplied reference material. Celsense remained privately held during its operating period. The company ceased operations on December 31, 2021. The available sources do not explain whether the closure resulted from insolvency, an acquisition, a strategic wind-down, unmet clinical objectives, or another cause. They also do not identify a successor company or confirm what happened to Celsense's intellectual property and imaging platforms. Celsense is therefore best characterized as a defunct biotechnology company whose documented legacy lies in commercializing university-originated cellular imaging technology and pursuing an early clinical application involving dendritic-cell therapy.

• 2021

  Operations ended

  [1]Celsenseen.wikipedia.org

  Celsense ceased operations on December 31, 2021.

• 2011

  FDA authorization for Phase I clinical trials

  [1]Celsenseen.wikipedia.org

  The company received authorization to begin Phase I clinical trials for a colorectal cancer treatment using therapeutic dendritic cells.

• 2005

  Company founded

  [1]Celsenseen.wikipedia.org

  Celsense was established in Pittsburgh to commercialize imaging platforms developed at Carnegie Mellon University.

A specialized biotechnology developer focused on imaging technologies for observing cells and cellular activity in living systems, with applications in cell therapy and biomedical research.

• Biotechnology imaging agents

  Cellular imaging agents

  Celsense developed imaging agents intended to detect and monitor cells and cellular activity non-invasively. These agents were positioned as research and potential clinical tools for observing biological processes in living systems, including applications connected with cell-based therapies. The available source does not identify a definitive commercial product name, formulation, approval status, or sales history.

• Biomedical imaging technology · 2005

  Cellular imaging platforms

  The company commercialized imaging platforms originating at Carnegie Mellon University. The platforms were designed to support non-invasive observation of cells and cellular activity, potentially helping researchers assess the distribution and behavior of cells used in therapeutic or experimental settings. Specific platform names, technical specifications, and commercialization arrangements are not confirmed in the available reference material.

• 2021

  Ended company operationsStrategy

  Background

  After operating as a privately held biotechnology company, Celsense reached the end of its documented corporate life.

  Action taken

  Celsense ceased operations on December 31, 2021.

  Aftermath

  No successor, acquirer, liquidation process, or subsequent owner of the company's technologies is identified in the available material.

  Source

• 2011

  Advanced a dendritic-cell treatment into Phase I clinical testingOther

  Background

  Celsense pursued a colorectal cancer treatment using therapeutic dendritic cells, supported by its cellular-imaging focus.

  Action taken

  The company obtained U.S. FDA authorization to begin Phase I clinical trials.

  Aftermath

  The available source does not report the trial results, subsequent clinical phases, or eventual regulatory approval.

  Source

• 2021

  Celsense ceased operations[1]Celsenseen.wikipedia.org

  Bankruptcy

  Celsense ended its operations on December 31, 2021.

• 2011

  Celsense received authorization to begin Phase I clinical trials involving therapeutic dendritic cells[1]Celsenseen.wikipedia.org

  Product launch · Regulation

  The U.S. Food and Drug Administration authorized Celsense to begin Phase I clinical trials for a colorectal cancer treatment using therapeutic dendritic cells.

1. 1Celsenseen.wikipedia.org